Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2013003697) METHOD FOR CONTROLLING TUMOR GROWTH, ANGIOGENESIS AND METASTASIS USING IMMUNOGLOBULIN CONTAINING AND PROLINE RICH RECEPTOR-1 (IGPR-1)
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2013/003697 International Application No.: PCT/US2012/044877
Publication Date: 03.01.2013 International Filing Date: 29.06.2012
IPC:
A61K 38/01 (2006.01) ,A61K 38/17 (2006.01) ,A61P 35/04 (2006.01) ,A61P 27/00 (2006.01) ,A61P 19/02 (2006.01) ,A61P 17/06 (2006.01) ,A61P 19/10 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
01
Hydrolysed proteins; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
04
specific for metastasis
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27
Drugs for disorders of the senses
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19
Drugs for skeletal disorders
02
for joint disorders, e.g. arthritis, arthrosis
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17
Drugs for dermatological disorders
06
Antipsoriatics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19
Drugs for skeletal disorders
08
for bone diseases, e.g. rachitism, Paget's disease
10
for osteoporosis
Applicants:
RAHIMI, Nader [US/US]; US
TRUSTEES OF BOSTON UNIVERSITY [US/US]; One Silber Way Boston, Massachusetts 02215, US (AllExceptUS)
Inventors:
RAHIMI, Nader; US
Agent:
EISENSTEIN, Ronald I.; Nixon Peabody LLP 100 Summer St. Boston, Massachusetts 02110-2131, US
Priority Data:
61/503,39230.06.2011US
Title (EN) METHOD FOR CONTROLLING TUMOR GROWTH, ANGIOGENESIS AND METASTASIS USING IMMUNOGLOBULIN CONTAINING AND PROLINE RICH RECEPTOR-1 (IGPR-1)
(FR) MÉTHODE DE RÉGULATION DE CROISSANCE TUMORALE, D'ANGIOGENÈSE ET DE MÉTASTASE À L'AIDE DU RÉCEPTEUR 1 RICHE EN PROLINE ET CONTENANT UNE IMMUNOGLOBULINE (IGPR-1)
Abstract:
(EN) The present invention provides methods and compositions for the treatment and prevention of angiogenesis, or cancer, e.g., metastatic cancer by administering an effective amount of an inhibitor of immunoglobulin containing proline rich receptor-1 (IGPR-1) protein or expression. In particular, the present invention provides methods and compositions for the treatment and prevention of cancer by administering an effective amount of an inhibitor of immunoglobulin containing proline rich receptor-1 (IGPR-1) protein or expression which is a soluble extracellular domain IGPR-1. Another aspects relates to methods and compositions comprising a IGPR-1 polypeptide or functional fragment thereof to promote angiogenesis in a subject in need thereof, e.g., for treatment of infarcts, retinopathy, AMD and the like.
(FR) La présente invention concerne des méthodes et des compositions pour le traitement et la prévention de l'angiogenèse, ou du cancer, par exemple d'un cancer métastatique, par administration d'une quantité efficace d'un inhibiteur d'une protéine ou de l'expression du récepteur 1 riche en proline contenant une immunoglobuline (IGPR-1). En particulier, la présente invention concerne des méthodes et des compositions pour le traitement et la prévention du cancer par administration d'une quantité efficace d'un inhibiteur d'une protéine ou de l'expression du récepteur 1 riche en proline contenant une immunoglobuline (IGPR-1) qui est un IGPR-1 à domaine extracellulaire soluble. D'autres aspects concernent des méthodes et des compositions comportant un polypeptide IGPR-1 ou un fragment fonctionnel de celui-ci pour favoriser l'angiogenèse chez un sujet qui en a besoin, par exemple, pour le traitement de l'infarctus, de la rétinopathie, de la dégénérescence maculaire liée à l'âge (AMD) et autres.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)